Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SEELOS THERAPEUTICS, INC. | v244221_ex99-1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 29, 2011
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
0-22245
|
87-0449967
|
||
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
11975 El Camino Real, Suite 300, San Diego, California
|
92130
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 222-8041
6330 Nancy Ridge Drive, Suite 103, San Diego, California 92121
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.01
|
Completion of Acquisition or Disposition of Assets
|
On December 29, 2011, Apricus Biosciences, Inc. ("Apricus Bio" or the “Company”) and Topotarget A/S, a Danish corporation (“Topotarget”) announced the closing of its acquisition of Topotarget USA, Inc., a subsidiary of Topotarget, a Danish company listed on the Copenhagen exchange.
Pursuant to the closing, Topotarget USA, Inc., based in Rockaway, New Jersey, will become a wholly-owned subsidiary of Apricus Bio. The Company also announced that it will change the name of Topotarget USA, Inc. to Apricus Pharmaceuticals USA, Inc. (“Apricus Pharma”).
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated December 29, 2011
|
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
December 29, 2011
|
Apricus Biosciences, Inc.
|
||
|
By:
|
/s/ RANDY BERHOLTZ
|
||
|
Randy Berholtz
|
|||
|
Executive Vice President, General Counsel and Secretary
|
|||